









Markets
/
Stocks
/
nasdaq-amlx
/

Amylyx Pharmaceuticals Inc

AMLX

13.980USD

+0.990+7.62%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.53BMarket Cap

LossP/E TTM



Amylyx Pharmaceuticals Inc

13.980

+0.990+7.62%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Amylyx Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Amylyx Pharmaceuticals Inc's fundamentals are relatively weak, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 69 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 20.22.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Amylyx Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

69 / 392

Overall Ranking

189 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Amylyx Pharmaceuticals Inc Highlights

StrengthsRisks

Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 293.03% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 87.37M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 87.37M.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Undervalued

The company’s latest PE is -7.80, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 113.87M shares, increasing 1.36% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 773.83K shares of this stock.

Analyst Rating

Based on 10 analysts

Strong Buy

Current Rating

20.222

Target Price

+55.68%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Amylyx Pharmaceuticals Inc is 5.42, ranking 368 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 52.70%.

Score

Industry at a Glance

Previous score

5.42

Change



Financials

2.66

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.75

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.97

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.68

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Amylyx Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Amylyx Pharmaceuticals Inc is 6.11, ranking 329 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -7.80, which is -5475.24% below the recent high of 419.35 and -153.91% above the recent low of -19.81.

Score

Industry at a Glance

Previous score

6.11

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 69/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Amylyx Pharmaceuticals Inc is 9.00, ranking 15 out of 392 in the Biotechnology & Medical Research industry. The average price target is 20.00, with a high of 25.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Strong Buy

Current Rating

20.222

Target Price

+55.68%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Amylyx Pharmaceuticals Inc

AMLX

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Amylyx Pharmaceuticals Inc is 7.18, ranking 95 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 17.06 and the support level at 11.34, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.97

Change

0.21

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.427

Neutral

RSI(14)

49.852

Neutral

STOCH(KDJ)(9,3,3)

21.829

Neutral

ATR(14)

1.170

Low Volatility

CCI(14)

-104.812

Sell

Williams %R

77.143

Sell

TRIX(12,20)

0.535

Sell

StochRSI(14)

61.088

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

14.002

Sell

MA10

14.413

Sell

MA20

14.434

Sell

MA50

13.507

Buy

MA100

13.648

Buy

MA200

10.319

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Amylyx Pharmaceuticals Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 99.16%, representing a quarter-over-quarter decrease of 3.45%. The largest institutional shareholder is The Vanguard, holding a total of 5.78M shares, representing 5.27% of shares outstanding, with 14.05% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

11.17M

+266.35%

Perceptive Advisors LLC

8.95M

+13.29%

Adage Capital Management, L.P.

6.82M

-22.54%

TCG Crossover Management, LLC

6.24M

+5.05%

BlackRock Institutional Trust Company, N.A.

6.01M

+23.95%

The Vanguard Group, Inc.

Star Investors

5.27M

+17.25%

Commodore Capital LP

5.65M

+38.63%

Saturn V Capital Management LP

4.60M

+41.23%

Cohen (Joshua Barry)

3.33M

-0.89%

Klee (Justin B)

3.33M

-0.89%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Amylyx Pharmaceuticals Inc is 5.25, ranking 51 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is -0.27. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Amylyx Pharmaceuticals Inc’s latest ESG disclosure is at an average level in the Biotechnology & Medical Research industry, showing no material impact on overall risk.